27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease is a neurological illness that impacts mental and emotional functions functions, has become a global concern due to its increasing prevalence. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a neurodegenerative disorder affecting millions globally, with early detection being critical for effective management. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a progressive neurodegenerative disorder that significantly impacts memory, cognition, and daily functioning. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's Disease acts as a degenerative brain trauma that results in poor memory, alongside impairing mental functioning. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a form of progressive dementia that significantly impacts the quality of life of patients and their families. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
While this process allows machine learning models to make more precise and reliable diagnoses, systems developed on the basis of Dr. Roman Poznanski's DOT (Dynamic Optimization of Thought) theory offer a new method in the diagnosis of neurological diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, AI has substantial potential to support more precise, person-centred care for older adults, but realising this promise will require multimorbidity-aware, transparent models, robust evaluation in diverse geriatric populations and governance frameworks that ensure fairness, privacy and meaningful human oversight. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Empowering family caregivers of patients with ADOD in a personalized DCEP provides durable reductions in patient hospitalizations and medical costs. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study proposes a deep learning-based framework to detect and classify Alzheimer's disease (AD) in the early stages using medical imaging, and specifically Magnetic Resonance Imaging (MRI). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease represents a major medical and social challenge owning to the complexity of its diagnosis, especially at the preclinical stage. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is the most common type of dementia and represents a significant global health problem due to its profound impact on patients' quality of life and the heavy burden it places on health care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The accurate diagnosis tends to remain critical for the improvement of the patient outcomes in the Alzheimer’s disease (AD), where a progressive neurodegenerative disorder with the growing of the global impact. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
To investigate the effect and mechanism of etomidate on attenuating Alzheimer-like neuropathology and cognitive impairment in mice with Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The integration of artificial intelligence in medical image classification has significantly advanced disease detection. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hexanucleotide repeat expansions in C9orf72 are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, yet the predictive information contained within associated inflammatory and proteinopathy markers remains incompletely characterised. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
AbstractO_ST_ABSBackgroundC_ST_ABSGlucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for type 2 diabetes. 5 key findings →
Participants: 6,328 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The feasibility criteria of >80% was met. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Neuropsychiatric symptoms (NPS) are increasingly recognized as critical components of the disease progression in Alzheimers disease (AD), yet their relationship with neurodegeneration remain poorly characterized. 2 key findings →
Participants: 1,756 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimers disease (AD) is characterized by substantial clinical and biological heterogeneity, with diverse neuroanatomical, cognitive, clinical, functional, and genetic risk profiles that are poorly captured by current diagnostic frameworks. 4 key findings →
Participants: 393 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Prior work suggests that perceived value may shape online support use, yet practical and trust-related barriers may still impede uptake even when beliefs are favorable. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BACKGROUNDSubjective cognitive decline (SCD) may precede mild cognitive impairment (MCI), but not all individuals with SCD progress to MCI. 5 key findings →
Design: longitudinal study Participants: 1,352 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
IntroductionFrontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. 2 key findings →
Design: longitudinal study Participants: 567 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Pain assessment remains challenging in clinical practice. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
An extra copy of the amyloid precursor protein gene (APP) is present in Down syndrome (DS) and APP duplication (APPdup), increasing the risk of Alzheimer disease (AD) and cerebral amyloid angiopathy (CAA). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Artificial intelligence can assist providers in a variety of patient care and intelligent health systems. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
10 of the 1,102 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →